OAM
JAZZ icon

Origin Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Origin Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-18,000
Closed -$1.79M – 97
2020
Q1 		$1.79M Sell
18,000
-27,300
-60% -$3.53M 0.23% 50
2019
Q4 		$6.76M Buy
+45,300
New +$6.16M 0.56% 50
2015
Q4 		– Sell
-57,960
Closed -$7.7M – 149
2015
Q3 		$7.7M Sell
57,960
-95,596
-62% -$16.5M 0.64% 51
2015
Q2 		$27M Sell
153,556
-6,673
-4% -$1.2M 1.97% 13
2015
Q1 		$27.7M Sell
160,229
-498
-0.3% -$85.5K 2.04% 8
2014
Q4 		$26.3M Sell
160,727
-22,701
-12% -$3.77M 2% 11
2014
Q3 		$29.5M Sell
183,428
-2,200
-1% -$338K 1.91% 15
2014
Q2 		$27.3M Buy
185,628
+91,519
+97% +$12.7M 1.77% 17
2014
Q1 		$13.1M Sell
94,109
-49,620
-35% -$7.47M 0.87% 48
2013
Q4 		$18.2M Sell
143,729
-121,112
-46% -$12.5M 1.22% 37
2013
Q3 		$24.4M Buy
264,841
+143,850
+119% +$11.6M 1.82% 20
2013
Q2 		$8.32M Buy
+120,991
New +$7.4M 0.72% 54

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Origin Asset Management's JAZZ Position: Q2 2020 in Review

Origin Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2020, closing a stake of 18,000 shares — an estimated $1.79M sold.

Origin Asset Management first reported a position in JAZZ in Q2 2013 and held it in 12 quarters. The position peaked at $29.5M in Q3 2014. 384 funds tracked by Wall St. Rank hold JAZZ as of Q2 2020.

  • Origin Asset Management reported no remaining Jazz Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Origin Asset Management sold 18,000 Jazz Pharmaceuticals shares in Q2 2020, an estimated $1.79M.
  • Origin Asset Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • Origin Asset Management's Jazz Pharmaceuticals position peaked at $29.5M in Q3 2014.
  • 384 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2020.

Based on Origin Asset Management's 13F filing for Q2 2020, filed 13 Aug 2020.